Rise and shine, everyone, another busy day is on the way. But busy is good, yes? Moreover, the tasks in front of us are made easier by a shiny sun and cool breeze enveloping the Pharmalot campus. This calls for celebratory cup of stimulation — chocolate cherry decadence is on tap — and, as always, we invite you to join us. Remember, no prescription is required. So there is no need to worry about those tiresome deductibles, copays, or rebates. Isn’t that nice? Meanwhile, here are some items of interest. Hope you have a swell day and please do keep in touch …

Eli Lilly (LLY) and AstraZeneca (AZN) ended two late-stage trials of an experimental drug for Alzheimer’s disease after the treatment failed to show any signs of working, adding to a litany of disappointments, Bloomberg News says. Like several others that failed, the drug targeted a protein called amyloid, thought to be a cause of the disease. The class of medicines known as BACE inhibitors operate before amyloid forms into deposits called plaques. Many researchers now believe that administering drugs after amyloid builds up in the brain may come too late to affect Alzheimer’s progress.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • If I may quote – “It is not yet clear, though, whether any drug companies have agreed to cut their prices voluntarily.” And if the ‘voluntary cuts’ will mean any more than ‘the voluntary 10% price caps’ that seem to have both come and gone with the wind. The day after Singapore, we may observe another exercise in ‘wind and optics,’ although without a signing ceremony.

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy